Moleculin’s $9.3m raise adds 49.5m potential shares after MIRACLE update

Moleculin Biotech, Inc. (Nasdaq: MBRX) reported a 37% blinded composite complete remission rate among 62 evaluable patients in the pivotal MIRACLE trial of Annamycin for relapsed or refractory acute myeloid leukemia. Less than three hours later, the company priced a $9.3 million public offering containing 12.38 million common-share equivalents and warrants covering another 37.13 million shares. Moleculin stock traded near $0.42 during the July 31 afternoon session, down approximately 58.6% from the previous close after falling below the offering’s $0.75 combined price. The clinical update suggests remission activity has persisted as more venetoclax-failed patients entered MIRACLE, but the financing structure demonstrates how urgently the company needs capital to reach the trial’s next unblinded analysis. The investment case now rests on whether the December 2026 to February 2027 Part A results can validate Annamycin before financing requirements and warrant dilution overwhelm the potential clinical value.

Blinded 37% remission signal holds after venetoclax failure but cannot isolate Annamycin’s effect

The July analysis included 62 evaluable patients from all three MIRACLE treatment groups. The pooled complete remission rate was 24%, while the broader composite complete remission rate was 37%. Thirty patients, or 48% of the evaluable population, had previously failed a venetoclax-based first-line regimen, and that subgroup produced a 23% complete remission rate and the same 37% composite remission rate as the overall population.

The stability is strategically useful because the blinded composite remission rate has remained between approximately 37% and 40% across analyses involving 30, 45 and 62 evaluable patients. During that period, the proportion of venetoclax-exposed participants increased from 31.1% to 48%, meaning the pooled signal did not deteriorate as the trial population became more difficult to treat.

The result does not establish Annamycin’s treatment effect. The 37% figure includes patients receiving either of two Annamycin doses plus high-dose cytarabine and patients receiving cytarabine plus placebo. Investors cannot determine from the blinded update how many remissions occurred in each arm or whether the favorable separation reported in June has persisted.

The June interim unblinding remains the more informative efficacy dataset. Among the first 45 patients, complete remission occurred in 43% of those receiving 190 mg/m² Annamycin and 36% receiving 230 mg/m², compared with 12% in the control group. Composite remission rates were 50%, 57% and 29%, respectively. The Independent Data Monitoring Committee concluded that both experimental arms showed a strong numerical advantage but had not reached formal statistical significance at that early analysis.

Moleculin compared the venetoclax-failed subgroup’s 37% pooled rate with a published salvage remission rate of approximately 13%. That comparison helps illustrate the severity of the population but cannot replace MIRACLE’s randomized control because the historical study was retrospective, single-center and used heterogeneous salvage treatments. The company also acknowledged that the subgroup analysis is descriptive and that MIRACLE is not powered to prove a treatment effect specifically among the 30 venetoclax-failed patients.

The clinical update therefore reduces one concern without resolving the principal valuation issue. Prior venetoclax treatment does not appear to have collapsed remission activity across the pooled study, but only the comprehensive unblinding can show whether Annamycin is responsible for the signal.

Why Moleculin’s $9.3 million offering created more dilution than financing certainty

Moleculin priced 12,376,667 common shares or pre-funded warrants together with warrants to purchase 37,130,001 additional shares. The combined offering price is $0.75 per share equivalent and associated warrants, while the new warrants carry a $0.75 exercise price, become immediately exercisable and remain outstanding for five years. The transaction is expected to close around August 3, subject to customary conditions.

The structure provides three warrant shares for every common share or pre-funded warrant sold. Full exercise of the new warrants could eventually provide approximately $27.85 million in additional gross proceeds, but that money is not committed. Moleculin would receive it only if warrant holders exercise, which generally requires the stock to trade at a level that makes exercise economically attractive.

The immediate dilution is already substantial. Moleculin had 5.34 million common shares outstanding at March 31 and sold another 354,757 shares through its at-the-market program in May. Using that approximate 5.69 million pre-offering basic share count, the 12.38 million new share equivalents equal about 2.17 times the existing count. Existing shareholders would represent only about 31.5% of the resulting basic share-equivalent total before considering exercise of the 37.13 million new warrants or older outstanding warrants. This is an estimate because the final mix of common shares and pre-funded warrants and any later share issuance may change the exact calculation.

Moleculin also entered the offering with a significant existing warrant overhang. Its March filing identified approximately 8.98 million Series G and Series H warrant shares containing price-adjustment provisions when equity is sold below their prevailing exercise prices. The July offering’s $0.75 price is below the stated adjustment floors of $1.326 for Series G and $0.962 for Series H, potentially lowering those exercise prices to their applicable floors while adding another layer of future dilution.

The market’s response indicates that investors assigned greater weight to the financing terms than to the clinical update. Moleculin traded near $0.42 during the afternoon, down roughly 58.6%, after moving between approximately $0.32 and $1.32 on volume approaching 18 million shares. The stock was trading well below the $0.75 offering price, although the securities sold in the financing also include substantial warrant value that ordinary shares purchased in the market do not provide.

A one-day move below $1 does not itself create a new Nasdaq deficiency. Sustained weakness could renew listing pressure, however, after Moleculin previously received minimum-bid and stockholders’ equity notices before regaining compliance in late 2025 and early 2026. A weaker share price would also make subsequent equity financing more dilutive.

Moleculin’s cash runway explains why the financing followed the MIRACLE update immediately

Moleculin held $10.3 million in cash and cash equivalents at March 31 and subsequently raised approximately $0.8 million through its at-the-market program. Management said those resources were sufficient only into the third quarter of 2026, placing the company close to the end of its disclosed runway as MIRACLE approached its final Part A enrollment.

The company used $6.1 million of cash in operating activities during the first quarter. Research and development spending increased to $5.4 million from $3.4 million a year earlier, primarily because of MIRACLE expenses in Europe and additional nonclinical studies. Moleculin generated no revenue and recorded an operating loss of $7.9 million.

The $9.3 million offering therefore represents bridge financing rather than long-term capitalization. Gross proceeds equal roughly one and a half quarters of first-quarter operating cash use, before placement fees, other transaction expenses and any increase in clinical costs as the trial moves toward Part B. Moleculin explicitly stated that it will require significant additional financing and has no commitments for the capital needed to conduct the broader clinical program.

The first-quarter filing also included substantial doubt about Moleculin’s ability to continue as a going concern. This accounting warning does not mean the company is expected to cease operations immediately, but it confirms that execution of the development plan depends on repeated access to external financing.

The timing of the two announcements is therefore understandable. The updated MIRACLE data gave Moleculin a clinical narrative to support an equity transaction, while the financing provided cash needed to treat the remaining Part A patients, analyze the complete dataset and prepare for continued development.

The transaction does not appear sufficient to finance the entire registration program. If the full Part A data are positive, Moleculin may seek another public offering, a licensing agreement or a strategic partner capable of funding Part B. If the results disappoint, the reduced stock price and expanded share base could make further financing considerably more difficult.

MIRACLE’s full Part A unblinding must confirm dose selection and randomized control separation

MIRACLE has enrolled 74 of its planned 90 Part A participants. Moleculin expects the final patient to be treated in September, with comprehensive unblinded results anticipated between December 2026 and February 2027. The larger review will include primary, secondary and exploratory endpoints and is intended to determine which Annamycin dose advances into Part B.

Part A compares 190 mg/m² and 230 mg/m² Annamycin, each combined with high-dose cytarabine, against cytarabine plus placebo. Data from the selected Annamycin arm in Part A are intended to carry forward into the pivotal Part B analysis, creating development efficiency if the dose-selection decision is reliable.

The primary endpoint is conventional complete remission after one treatment cycle rather than composite remission. That distinction matters because the July headline emphasized the 37% composite rate, while the final approval case will depend heavily on whether the selected Annamycin dose produces a statistically credible improvement in the protocol’s primary remission endpoint relative to the concurrent control.

The initial 45-patient analysis was intentionally conducted under a conservative group-sequential design and was not expected to reach statistical significance. The complete trial is planned to include approximately 282 participants and is designed with 80% power to detect an improvement from a 20% control complete-remission rate to 35% with the selected experimental regimen.

The next analysis must answer several questions that the July update could not address. Investors need to see whether the experimental-control separation remains intact after the population doubles, whether one dose offers a clearer safety or efficacy advantage and whether response duration, survival and transplantation outcomes support the clinical importance of remission.

The control arm also requires attention. Its 29% composite remission rate in the June analysis exceeded some historical assumptions, although its 12% conventional complete remission rate remained below both Annamycin arms. A stronger control performance in the final Part A population could narrow the treatment difference and increase the sample size or execution required in Part B.

Annamycin’s commercial value depends on cardiac differentiation and a strategic partner

Annamycin is a liposomal anthracycline designed to avoid multidrug-resistance mechanisms and reduce the cardiotoxicity associated with conventional drugs in the class. Moleculin reported no evidence of cardiotoxicity in the continuing MIRACLE trial and previously disclosed an independent pooled assessment of 90 treated patients across five trials. Among 78 patients with verified pre-treatment and post-treatment ejection-fraction measurements, the company reported no cases meeting the assessment criteria for clinically significant left ventricular dysfunction.

Cardiac differentiation could become commercially important in relapsed AML, where patients may be older, medically vulnerable or previously exposed to anthracyclines. A treatment capable of delivering anthracycline activity without cumulative cardiac damage might support broader eligibility, repeat dosing or combination strategies.

The evidence remains preliminary. The absence of an observed signal in 90 patients cannot exclude rare events or prove safety during longer exposure, and Moleculin has relied on an independent expert’s assessment rather than a completed registrational safety database. The full MIRACLE analysis must show that cardiac advantages are accompanied by a clinically meaningful improvement in remission and later outcomes.

Annamycin has FDA Fast Track status and orphan designation in relapsed or refractory AML, European orphan designation and composition-of-matter patent protection through 2040, with potential extension to 2045. These protections could support premium rare-oncology economics if the therapy reaches approval.

Moleculin does not own manufacturing facilities and has no commercial sales organization. Its stated strategy is to seek out-licensing or strategic partners better positioned to manufacture, distribute and sell its candidates. Positive full Part A data could therefore create value by improving partnership terms, reducing the amount of development capital Moleculin must provide directly and validating Annamycin as a licensable late-stage asset.

The July financing demonstrates that Moleculin may not have the balance-sheet leverage to wait indefinitely for an optimal partnership. The company must obtain enough capital to keep MIRACLE progressing while avoiding agreements that surrender excessive economics before the pivotal evidence is available.

The 37% blinded remission rate supports continued interest in the program, particularly because it held among patients who previously failed venetoclax. The $9.3 million offering reveals the other side of the investment case: clinical promise is being financed through a structure capable of multiplying the share count many times over. Full Part A results must now create enough value to overcome that dilution and attract capital on materially better terms.

Key takeaways from Moleculin’s MIRACLE data, financing and dilution outlook

• MIRACLE reported a 37% blinded composite remission rate among 62 evaluable patients, including the same rate among 30 patients who previously failed venetoclax.
• The pooled result includes the cytarabine control group and therefore cannot establish Annamycin’s treatment effect.
• June’s unblinded analysis showed composite remission rates of 50% and 57% in the two Annamycin arms versus 29% for control, although the early comparison was not statistically significant.
• Moleculin priced a $9.3 million offering containing 12.38 million common-share equivalents and warrants covering 37.13 million additional shares.
• The new share equivalents are roughly 2.2 times Moleculin’s estimated pre-offering basic share count, reducing existing holders to about 31.5% of the pro forma basic total before warrant exercises.
• Full exercise of the new warrants could generate approximately $27.85 million, but that capital is uncertain and depends on the future share price and investor decisions.
• Moleculin stock fell approximately 59% to around $0.42, placing it below the offering price and renewing concerns about dilution, financing access and potential future listing compliance.
• The company had $10.3 million in March cash, used $6.1 million in first-quarter operations and previously projected that available resources would last only into the third quarter.
• Full Part A enrollment is expected in September, with comprehensive unblinded results planned between December 2026 and February 2027.
• Annamycin’s long-term value depends on preserving the randomized remission advantage, validating its cardiac-safety differentiation and securing a partner capable of financing and commercializing the program.